Key facts
- This page summarizes Astrid Borkowski's Form 4 filing for HilleVax, Inc. (HLVX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Feb 2024, 19:35.
Astrid Borkowski - 08 Feb 2024 Form 4 Insider Report for HilleVax, Inc. (HLVX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- HLVX
- Reported as of
- 08 Feb 2024
- Net transaction value
- -$58,726
- SEC form
- 4
- Accepted by SEC
- 12 Feb 2024, 19:35:46 UTC
- Prior SEC filing
- 18 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Bavier, Attorney-in-Fact for Astrid Borkowski
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Astrid Borkowski filed Form 4 for HilleVax, Inc. (HLVX) on 12 Feb 2024.
Change
- Previous filing in this sequence was filed on 18 Dec 2023.
- Current net transaction value: -$58,726.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HLVX
transaction
Common Stock
Sale
- Transaction value
- $58,726
- Shares
- -3,933
- Change %
- -2.4%
- Price
- $14.93
- Shares after
- 161,260
- Date
- 08 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
HLVX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +53,632
- Change %
- +33%
- Price
- $0.000000
- Shares after
- 214,892
- Date
- 08 Feb 2024
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HLVX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +69,852
- Change %
- Price
- $0.000000
- Shares after
- 69,852
- Date
- 08 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,852
- Exercise price
- $15.06
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units ("RSUs"), which sale was mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price.
Footnote F3
Represents RSUs which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 8, 2024, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.
Footnote F4
The option is exercisable as it vests. The option will vest with respect to 25% of the shares of common stock on February 8, 2025 and will vest with respect to the remaining shares in equal monthly installments over the following three years subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.